Cheaper Drug for Heart Attack Could Improve Outcomes and Save Millions
Liverpool, UK - A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes - such as a reduced rate of repeat heart attacks - compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries. Bivalirudin is around 400 times more expensive than heparin.
The results of the HEAT-PPCI trial suggest that systematic use of heparin rather than bivalirudin after primary percutaneous coronary intervention (PPCI) – the most commonly used treatment for heart attack, which unblocks the arteries carrying blood to the heart – could save health services substantial sums of money, at the same time as potentially improving patient outcomes.
Patients who undergo PPCI usually receive a combination of antithrombotic drugs to prevent any further blood clots forming during the procedure and after it has been completed. The most commonly used antithrombotic drugs are unfractionated heparin and bivalirudin, and although several previous trials have compared the two drugs, the evidence is unclear as to which drug results in better outcomes.
The trial took place at the Liverpool Heart and Chest Hospital in the UK, where 1829 patients undergoing emergency angiography (an x-ray examination of the heart's arteries after a suspected heart attack) were recruited to the trial. More than four fifths of these patients then went on to receive PPCI; approximately half received heparin, and half received bivalirudin. Researchers then recorded how many patients in both groups experienced a major adverse cardiac event, such as death or another heart attack, within 28 days after surgery. Continue>
Posted in: Pharma | November 4, 2013
Posted in: Pharma | November 18, 2014
Posted in: Pharma | August 21, 2015